The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to stcric stabiliation of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigcnic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.
